Возможный алгоритм ведения больных раком предстательной железы в условиях пандемии коронавирусной инфекции
https://doi.org/10.17650/1726-9776-2020-16-1-124-128
Аннотация
Об авторах
В. Б. МатвеевРоссия
115478 Москва, Каширское шоссе, 24
М. И. Волкова
Россия
Мария Игоревна Волкова
115478 Москва, Каширское шоссе, 24
О. П. Трофимова
Россия
115478 Москва, Каширское шоссе, 24
С. И. Ткачёв
Россия
115478 Москва, Каширское шоссе, 24
Список литературы
1. Liang W., Guan W., Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7. DOI: 10.1016/S1470-2045(20)30096-6.
2. Ueda M., Martins R., Hendrie P.C. et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020:1–4. DOI: 10.6004/jnccn.2020.7560.
3. Care of prostate cancer patients during the COVID-19 pandemic: recommendations of the NCCN. Available at: https://www.nccn.org/covid-19/pdf/ NCCN_PCa_COVID_guidelines.pdf.
4. Gupta N., Bivalacqua T.J., Han M. et al. Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to veryhigh-risk clinically localised prostate cancer. BJU Int 2019;124(2):268–74. DOI: 10.1111/bju.14659.
5. Denham J.W., Steigler A., Lamb D.S. et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12(5):451–9. DOI: 10.1016/S1470-2045(11)70063-8.
6. Widmark A., Gunnlaugsson A., Beckman L. et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019;394(10196):385–95. DOI: 10.1016/S0140-6736(19)31131-6.
7. Parker C.C., James N.D., Brawley C.D. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392(10162):2353–66. DOI: 10.1016/S0140-6736(18)32486-3.
8. Клинические рекомендации по лечению рака предстательной железы Ассоциации онкологов России 2019. Доступно по: https://oncologyassociation.ru/new-clinical-guidelines. [Clinical Guidelines for the treatment of prostate cancer of the Association of Oncologists of Russia 2019. Available at: https://oncology-association.ru/newclinical-guidelines. (In Russ.)].
9. Chi K.N., Agarwal N., Bjartell A. et al. Apalutamide for metastatic, castrationsensitive prostate cancer. N Engl J Med 2019;381(1):13–24. DOI: 10.1056/NEJMoa1903307.
10. Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33.
11. Gravis G., Fizazi K., Joly F. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149–58. DOI: 10.1016/S1470-2045(12)70560-0.
12. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X.
Рецензия
Для цитирования:
Матвеев В.Б., Волкова М.И., Трофимова О.П., Ткачёв С.И. Возможный алгоритм ведения больных раком предстательной железы в условиях пандемии коронавирусной инфекции. Онкоурология. 2020;16(1):124-128. https://doi.org/10.17650/1726-9776-2020-16-1-124-128
For citation:
Matveev V.B., Volkova M.I., Trofimova O.P., Tkachev S.I. Potential algorithm of prostate cancer management during the pandemic of coronavirus infection (COVID-19). Cancer Urology. 2020;16(1):124-128. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-1-124-128